Clinical Trials
8 trialsNCT01155583 2020-11-16
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01212952 2020-04-17
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00049504 2017-05-17
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00899080 2017-05-17
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Eastern Cooperative Oncology Group
Completed
NCT00942422 2015-03-27
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT01055301 2015-03-06
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00900406 2012-11-06
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Completed
NCT00482495 2011-05-11
Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed